A three-decade-old Maharashtra specialty-chemicals maker opens its Rs 500 crore mainboard issue on September 8
A forward-integrated manufacturer of acetone- and phosphorus-based specialty chemicals plans to raise Rs 500 crore via a mainboard listing on BSE and NSE.
Prasol Chemicals Ltd, incorporated in 1992 and operating two large-scale facilities in Maharashtra, opens for subscription on September 8 with the issue closing on September 10.
It operates in the specialty-chemicals industry as a forward-integrated manufacturer of acetone- and phosphorus-based specialty chemicals, alongside other specialty products involving complex, differentiated chemistries.
It is a highly diversified player, with over 150 specialty chemical products, over 1,600 customers, and exports to 69 countries as of mid-2026 — breadth that reduces dependence on any single product, customer or end-market.
It comprises 21 acetone-based specialty chemicals (acetone being a colourless, highly volatile organic compound), 53 phosphorus-based specialty chemicals (phosphorus being a highly reactive element), and 76 other specialty products including surfactants, performance additives, ethers, esters, polymers and acids.
These serve five key application segments: performance chemicals (lubricant additives, mining chemicals); PICA (paints, inks, construction and adhesives); pharmaceuticals; agrochemicals; and home and personal care.
The manufacturing base is certified and scalable. Prasol operates two large-scale certified facilities in Maharashtra with an aggregate installed capacity of 98,644 MTPA, supported by an additional expandable facility at Dheku — built on strong quality systems, regular customer audits and sustainable processes.
It is certified as a 3-Star Export House with a global distribution network across APAC, the Americas and Europe.
The competitive moat is real. As Anand Rathi notes, the specialty-chemicals business benefits from high entry barriers — lengthy 1–4 year customer approval cycles, complex chemistry, high product-development costs and stringent regulatory requirements — which create significant customer stickiness and make displacing established suppliers difficult, supporting long-term revenue visibility.
Its marquee customer base includes Alembic Pharmaceuticals, Lubrizol India, Rossari Biotech, Clean Science, Gharda Chemicals, Croda India, Supriya Lifescience and Yasho Industries.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | September 8, 2026 |
| Issue Closes | September 10, 2026 |
| Listing | BSE, NSE (Mainboard) |
| Listing Date | September 16, 2026 |
| Price Band | Rs 643 – Rs 676 per share |
| Face Value | Rs 2 |
| Issue Size | Rs 500 crore (~73,96,437 shares) |
| Fresh Issue | Rs 80 crore (~11.8 lakh shares) |
| Offer for Sale | Rs 420 crore (~62.1 lakh shares) |
| Min. Application | 22 shares (multiples thereafter) |
| Min. Retail Investment | Rs 14,872 |
| Post-Issue Market Cap | Rs 4,000.8 crore |
| Lead Manager | DAM Capital Advisors Ltd. |
| Registrar | KFin Technologies Ltd. |
The issue is dominated by the OFS. From the fresh proceeds (Rs 80 crore), the company will use funds for repayment or prepayment of certain borrowings and general corporate purposes; the OFS accounts for Rs 420 crore. So around 84% of the raise goes to selling shareholders rather than into the business — a key caveat.
Post-issue, promoter and promoter group shareholding falls from 89.2% to 76.9%, with public shareholding rising to 23.1%.
Price Band Analysis
At the upper band of Rs 676, on FY26 earnings the issue is valued at a P/E of about 48x, for a post-issue market cap of approximately Rs 4,000 crore (Rs 40,008 million) — which, as per Anand Rathi, makes the issue appear fully priced. The company reported an EPS of Rs 14.33, a NAV of Rs 77.33 and RoNW of 18.5%.
According to a note by Anand Rathi Research, “on the valuation front, based on FY26 earnings, the company is seeking a P/E of 48x times, and a post-issue market capitalization of approximately Rs 40,008 million, making the issue appears to be fully priced. However, their business is dependent on manufacturing facilities wherein unplanned shutdown happens creating disruption in operational activities. Overall strong product depth, R&D-led innovation and a diversified global customer base position the company well to capture long-term growth opportunities in specialty chemicals. Hence, we assign a ‘Subscribe for Long Term’ rating for the issue.”
GMP Watch
Grey-market interest has been strong but highly volatile. In tracked data, the Prasol Chemicals IPO GMP ranged widely from a low of ₹13–14 (September 3) to a high of ₹120–150 (September 7), before settling sharply lower to around ₹55 (~8% premium).
As always, GMP is unofficial, unregulated and unendorsed, and for a large issue can move sharply on shifting sentiment before QIB and final-day demand crystallises.
Financial Performance
| Particulars (Rs million) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from Operations | 8,766 | 10,125 | 12,326 |
| EBITDA | 605 | 878 | 1,393 |
| EBITDA Margin (%) | 6.9 | 8.7 | 11.3 |
| PAT | 181 | 436 | 831 |
| PAT Margin (%) | 2.1 | 4.3 | 6.7 |
| EPS (Rs) | 3.1 | 7.5 | 14.3 |
Revenue from operations grew from Rs 8,766 million in FY24 to Rs 12,326 million in FY26 (up 21.7% in FY26), while the profit expansion was much sharper — PAT rose from Rs 181 million to Rs 831 million, roughly 4.6x over two years, aided by steady margin expansion.
EBITDA margin improved from 6.9% to 11.3%, and PAT margin from 2.1% to 6.7%, over the three fiscals — a genuine operating-leverage story as the forward-integrated model scaled.
The improving margin profile and rising return ratios (reviewers cite RoE ~20.4%, RoCE ~22.4% and a low debt-to-equity of ~0.19) reflect a strengthening, deleveraged business. The main valuation tension is that even after this profit surge, the ask of ~48x FY26 earnings is full — the investment case therefore rests heavily on sustained earnings growth after listing.
Peer Comparison
| Company | Revenue FY26 (Rs mn) | EPS (Rs) | P/E | RoNW (%) |
|---|---|---|---|---|
| Prasol Chemicals | 12,326 | 14.33 | 48.4* | 18.5 |
| Aarti Industries | 82,860 | 11.56 | 46.75 | 7.0 |
| Atul Ltd. | 62,735 | 230.25 | 28.04 | 11.0 |
| Laxmi Organic Industries | 28,467 | 2.87 | 59.74 | 4.0 |
| Vinati Organics | 22,269 | 42.80 | 30.95 | 14.0 |
| Privi Speciality Chemicals | 25,637 | 81.08 | 42.67 | 22.0 |
| Yasho Industries | 8,300 | 20.95 | 206.68 | 5.7 |
| Excel Industries | 10,945 | 60.19 | 17.12 | 4.4 |
Against the listed specialty-chemicals peer set, Prasol’s ~48x P/E sits at the higher end, though its 18.5% RoNW is among the strongest in the group — a combination that gives the premium partial cover, but leaves the valuation demanding versus larger, more established names like Atul and Vinati.
Risks to Consider
At Rs 420 crore of a Rs 500 crore issue (~84%), the vast majority goes to selling shareholders rather than the business, with only Rs 80 crore of fresh capital — so this is substantially a shareholder-exit event.
Full valuation limits the cushion. At ~48x FY26 earnings, the pricing is rich even after the strong profit growth, and the investment case depends on sustained earnings momentum post-listing; any slowdown would expose the multiple.
Manufacturing and operational disruption risk is real. Both facilities are in Maharashtra, with prior MPCB-directed shutdowns and Mahad losses of Rs 122 million in FY2026 — unplanned shutdowns could disrupt production and financial performance.
End-market demand risk is structural. Demand depends on customers’ end products, with acetone-based and phosphorus-based chemicals contributing 42.8% and 38.3% of FY2026 revenue respectively — a concentration in two chemistries that ties fortunes to those end-markets.